Aspen Neuroscience
PrivateLast Round
Series C
Nov 20, 2025
Total Funding Raised
$387M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Aspen Neuroscience is a biotechnology company that develops autologous cell therapies and personalized medicines aimed at treating a wide range of diseases, beginning with Parkinson's disease, through the use of advanced genomic AI and pluripotent stem cell biology for patient-specific restorative treatments.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Aspen Neuroscience Comparables
Compare Aspen Neuroscience with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Kenai Therapeutics | 86% | |
| Bayer AG | 83% | |
| Sumitomo Pharma Co., Ltd. | 71% | |
Aspen Neuroscience Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Nov 20, 2025 | ||||
| Grant | May 15, 2024 | ||||
| Debt | Dec 21, 2022 | ||||
| Series B | May 9, 2022 | ||||
| Series A | Apr 1, 2020 | ||||
Seed | Dec 12, 2019 |
Key People
Founding team and executive leadership
Aspen Neuroscience Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| S32 | Series B, Seed, Series C, Series A |
| Conrad Prebys Foundation | Series C |
| Balyasny Asset Management L.P. | Series C |
| Prebys Ventures | Series C |
| Frazier Healthcare Partners | Series A |
| GV | Series B |
| Cormorant Asset Management | Series C |
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 18, 2026
New 12-month data released from ASPIRO trial of sasineprocel.
- Mar 18, 2026
Presented at the AD/PD 2026 International Conference in March 2026.
Aspen Neuroscience Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Aspen Neuroscience's valuation, stock price, and market status.